Suppr超能文献

普萘洛尔与甲状腺毒症的高钙血症

Propranolol and the hypercalcaemia of thyrotoxicosis.

作者信息

Feely J

出版信息

Acta Endocrinol (Copenh). 1981 Dec;98(4):528-32. doi: 10.1530/acta.0.0980528.

Abstract

The effect of propranolol on serum calcium was studied in 25 patients with thyrotoxicosis including 5 with hypercalcemia. In patients with hypercalcaemia iv propranolol significantly reduced serum calcium. Oral therapy 160 mg/day reduced calcium non-significantly from 2.72 +/- 0.09 (mean +/- SD) to 2.59 +/- 0.13 mmol/l, however on 320 mg/day the reduction (to 2.5 +/- 0.15 mmol/l) was significant. In normocalcaemic patients oral propranolol did not influence serum calcium. Both in hyper- and normocalcemic thyrotoxic patients propranolol increased (P less than 0.01) serum phosphate.

摘要

对25例甲状腺毒症患者(其中5例伴有高钙血症)研究了普萘洛尔对血清钙的影响。在高钙血症患者中,静脉注射普萘洛尔可显著降低血清钙。口服疗法,每日160毫克,可使血钙从2.72±0.09(均值±标准差)毫摩尔/升降至2.59±0.13毫摩尔/升,降幅不显著,然而每日320毫克时,血钙降至2.5±0.15毫摩尔/升,降幅显著。在血钙正常的患者中,口服普萘洛尔不影响血清钙。在甲状腺毒症伴高钙血症和血钙正常的患者中,普萘洛尔均可使血清磷酸盐升高(P<0.01)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验